| Popis: |
Makuch Marcin, Makuch Marcelina, Kordyga Aleksandra, Trojnar Marcin. Neuroleptic malignant syndrome – a case report. Journal of Education, Health and Sport. 2019;9(7):159-166. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.3269154 http://ojs.ukw.edu.pl/index.php/johs/article/view/7116 https://pbn.nauka.gov.pl/sedno-webapp/works/917415 The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26/01/2017). 1223 Journal of Education, Health and Sport eISSN 2391-8306 7 © The Authors 2019; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 20.06.2019. Revised: 25.06.2019. Accepted: 04.07.2019. Neuroleptic malignant syndrome – a case report Marcin Makuch1, Marcelina Makuch2, Aleksandra Kordyga3, Marcin Trojnar1 1 Chair and Department of Internal Medicine, Medical University of Lublin, Poland 2 Chair and Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland 3 II Chair of Psychiatry and Psychiatric Rehabilitation, Medical University of Lublin, Poland Corresponding author: Marcin Makuch ul. Staszica 16, 20-081 Lublin, Poland, e- mail: marcinm45@gmail.com ABSTRACT Neuroleptic malignant syndrome (NMS) is rare, but potentially lethal complication associated with the use of neuroleptic agents. NMS is most often observed after high-potency first-generation neuroleptic agents. NMS is characterised by a distinctive clinical syndrome including: hyperthermia, muscular rigidity, mental status change, autonomic disability. The most common laboratory finding is elevated serum CK. The management of patients with NMS demands aggressive care and discontinuing of the causative agent. A 49-year-old patient with recurrent depressive disorders is presented. NMS developed following the increase in haloperidol dose and concomitant use of olanzapine. The treatment with bromocriptine and lorazepam resulted in a prompt recovery. Key words: neuroleptic malignant syndrome, hyperthermia, elevated serum CK |
